سعر ريفاروسبير 15مجم 42 قرص 2023
Rivarospire 15 mgالفئة: مضاد للتجلط
معلومات الدواء
التفاصيل الكاملةدواعي الاستعمالUses
- Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation (15 mg dose for CrCl 50 mL/min or less)الفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Treatment of deep vein thrombosis and pulmonary embolism (initial 21 days)الفئة: AdultsDailyMed (U.S. National Library of Medicine)
- Reduction of risk of stroke and systemic embolism in nonvalvular atrial fibrillation (15 mg dose for CrCl 50 mL/min or less)Population: AdultsDailyMed (U.S. National Library of Medicine)
- Treatment of deep vein thrombosis and pulmonary embolism (initial 21 days)Population: AdultsDailyMed (U.S. National Library of Medicine)
الآثار الجانبيةSide effects
- The most common adverse reactions are bleeding complications.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- The most common adverse reactions are bleeding complications.International label, same formulation · DailyMed (U.S. National Library of Medicine)
موانع الاستعمالContraindications
- Active pathological bleeding.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.نشرة دولية لنفس التركيبة · European Medicines Agency
- Active pathological bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Severe hypersensitivity reaction to rivaroxaban (e.g. anaphylaxis).International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Lesion or condition at significant risk of major bleeding; concomitant treatment with any other anticoagulant except when switching; hepatic disease associated with coagulopathy (incl. Child-Pugh B and C cirrhosis); pregnancy and breast-feeding.International label, same formulation · European Medicines Agency
تحذيرات واحتياطاتWarnings & precautions
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Boxed warning: premature discontinuation increases the risk of thrombotic events; consider coverage with another anticoagulant.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Boxed warning: epidural or spinal haematomas, which may cause long-term or permanent paralysis, can occur with neuraxial anaesthesia or spinal puncture.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Increased risk of bleeding, including serious or fatal bleeding; risk increased with aspirin, P2Y12 inhibitors, other antithrombotics, fibrinolytics, NSAIDs, SSRIs and SNRIs.International label, same formulation · DailyMed (U.S. National Library of Medicine)
التداخلات الدوائيةDrug interactions
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inhibitors (e.g. ketoconazole, ritonavir)Increase rivaroxaban exposure and bleeding risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Combined P-gp and strong CYP3A inducers (e.g. carbamazepine, phenytoin, rifampin, St John's wort)Decrease rivaroxaban exposure and may increase thromboembolic risk; avoid concomitant use.DailyMed (U.S. National Library of Medicine)
- Anticoagulants, aspirin, clopidogrel and NSAIDsCoadministration may increase bleeding risk; avoid other anticoagulants unless benefit outweighs risk and evaluate promptly any signs of blood loss.DailyMed (U.S. National Library of Medicine)
الحمل والرضاعةPregnancy & breastfeeding
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.نشرة دولية لنفس التركيبة · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.نشرة دولية لنفس التركيبة · DailyMed (U.S. National Library of Medicine)
- Limited data are insufficient to inform drug-associated developmental risk; use with caution in pregnancy because of potential pregnancy-related haemorrhage and/or emergent delivery.International label, same formulation · DailyMed (U.S. National Library of Medicine)
- Contraindicated during pregnancy because of potential reproductive toxicity, intrinsic bleeding risk and placental passage; women of child-bearing potential should avoid becoming pregnant during treatment.International label, same formulation · European Medicines Agency
- Rivaroxaban has been detected in human milk; insufficient data on effects on the breastfed child; weigh benefits of breastfeeding against maternal need.International label, same formulation · DailyMed (U.S. National Library of Medicine)
المثائل (3)
كل المثائل والبدائلنفس المادة الفعالة والتركيز. اسأل الصيدلي قبل الاستبدال.
| الدواء | السعر | الفرق عن الأصلي |
|---|---|---|
| اندوريفابان 15 مجم 20 قرصAndorivaban 15 mg 20 tabletsAl Andalous Pharmaceutical Industries · أقراص · 15 mgالأرخص | السعر260ج.م13ج.م للوحدة | الفرق عن الأصليأرخص 274ج.م (51.3%) |
| اورجوركسابان 15مجم 20 قرصOrgoroxabanOrganopharma · أقراص مغلفة · 15 mg | السعر342ج.م17.1ج.م للوحدة | الفرق عن الأصليأرخص 192ج.م (36%) |
| ريباتوكسابان 15مجم 30 قرصRepatoxaban 15 mg 30 tabsEva Pharma · 15 mg | السعر360ج.م12ج.م للوحدة | الفرق عن الأصليأرخص 174ج.م (32.6%) |
المعرّفات
- الباركود
- 6224000866495
أدوية ذات صلة
نفس المادة الفعالة بتركيز آخر
منتجات أخرى من Inspire Pharmaceutical Company
المصادر
- السعر: قوائم أسعار الأدوية المنشورة في مصر.
- DailyMed (U.S. National Library of Medicine)
- European Medicines Agency
تعليقات
لا توجد تعليقات بعد. كن أول من يشارك تجربته مع هذا الدواء.
أضف تعليقًا